ESC/ESH 2023 Hypertension Guidelines: Key Updates on Targets and Therapy

Abstract

The 2023 Guidelines for the management of arterial hypertension, co-published by the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH), introduce key updates aimed at simplifying and optimizing clinical practice. 

This review outlines the significant revisions, focusing on refined blood pressure (BP) treatment targets and a reinforced stepped-care pharmacologic strategy. The guidelines reaffirm the diagnostic thresholds and emphasize the importance of out-of-office BP measurement. 

Crucially, the target for most treated adults remains a systolic BP goal of 130–120 mmHg and a diastolic BP target of <80 mmHg, with specific adjustments for the elderly and patients with comorbidities. 

The most impactful therapeutic shift is the Class I recommendation for initiating treatment with a single-pill combination (SPC) for the majority of patients, leveraging the synergy of dual therapy to rapidly achieve control and improve adherence. 

The goal is to move efficiently through the therapeutic steps—Dual, Triple, and then Resistant—to minimize cardiovascular risk, cementing an aggressive, evidence-based approach to long-term BP control.

Introduction: Shifting Paradigms in Hypertension Management 

Arterial hypertension remains the leading preventable cause of premature death and disability worldwide, primarily driven by its association with myocardial infarction, stroke, heart failure, and chronic kidney disease. 

Globally, over one billion adults are affected, and the prevalence continues to rise, underscoring the critical need for effective diagnosis and management. The goal of hypertension therapy is to reduce total cardiovascular risk by achieving and maintaining long-term blood pressure (BP) control. 

The 2023 European Society of Cardiology (ESC) and European Society of Hypertension (ESH) Guidelines represent a concerted effort to refine existing strategies, moving toward a more streamlined, aggressive, and evidence-based approach that maximizes BP-lowering efficacy while simultaneously enhancing patient adherence. 

The core paradigm shifts include a renewed focus on precise BP targets and the strong endorsement of initial single-pill combination (SPC) therapy for the majority of patients, simplifying the management pathway based on recent robust clinical trial data.

Diagnosis and Blood Pressure Assessment 

Accurate and consistent measurement of blood pressure (BP) is foundational to the diagnosis and subsequent management of arterial hypertension. 

The 2023 ESC/ESH Guidelines maintain the established diagnostic BP thresholds, but place increased emphasis on corroborating out-of-office measurements to confirm the diagnosis and rule out white-coat or masked hypertension.

Defining Arterial Hypertension: Thresholds for Office vs. Ambulatory BP (ABPM/HBPM)

The guidelines classify hypertension based on seated, standardized office BP measurements. Stage 1 hypertension is defined as an office systolic BP (SBP) of 140-159 mmHg or diastolic BP (DBP) of 90-99 mmHg. Stage 2 and Stage 3 correspond to progressively higher thresholds.

Optimal Diagnostic Strategy: The Role of ABPM and HBPM in Confirmation 

The guidelines give a Class I, Level A recommendation for confirming the diagnosis of hypertension using Ambulatory Blood Pressure Monitoring (ABPM), whenever possible, or at least Home Blood Pressure Monitoring (HBPM).

• White-Coat Hypertension: Defined by elevated office BP (≥ 140/90 mmHg) but normal daytime ABPM (≤ 135/85 mmHg). These individuals often have a lower cardiovascular risk profile than those with sustained hypertension, though close monitoring is required.
  
  
• Masked Hypertension: Defined by normal office BP (≤ 140/90 mmHg) but elevated out-of-office BP. This profile is associated with a cardiovascular risk similar to, or even higher than, sustained hypertension, making out-of-office confirmation critical.
  
  

Risk Stratification: Integrating BP Level and Total Cardiovascular Risk 

The management intensity is dictated not solely by BP level, but by the patient’s total cardiovascular risk. Risk stratification integrates the BP category with the presence of:

1. Risk Factors: Age, sex, smoking status, dyslipidemia, diabetes mellitus (DM).
   
   
2. Hypertension-Mediated Organ Damage (HMOD): Left ventricular hypertrophy (LVH), chronic kidney disease (CKD, e.g., microalbuminuria or reduced estimated glomerular filtration rate [eGFR]), and established vascular disease.
   
   
3. Established Cardiovascular or Renal Disease: Previous stroke, myocardial infarction, coronary artery disease (CAD), or severe CKD.
   
   

Patients with Stage 1 hypertension and established CVD are immediately categorized as High or Very High Risk, necessitating prompt and often aggressive therapeutic intervention based on strong trial evidence.

Updated Blood Pressure Treatment Targets 

The 2023 ESC/ESH Guidelines refine and solidify the recommended blood pressure (BP) targets, emphasizing a lower, yet individualized, approach to maximize cardiovascular protection, largely substantiated by data from trials like SPRINT and HOPE-3. 

The strategy is built on two principles: first, initiating treatment promptly once diagnostic thresholds are met, and second, achieving target goals within a three-month period.

General Adult Population Targets 

For the majority of treated adults (age 18–79 years), the guidelines advocate for a staged reduction in BP to prevent excessive hypotension while still benefiting from lower targets.

• Initial Target: In the first phase of treatment, the SBP should be lowered to <140 mmHg.
  
  
• Optimal Target: Once tolerated, the SBP target should be further reduced to 130–120 mmHg. An SBP target of <120 mmHg is discouraged due to the risk of adverse events and lack of clear benefit in the general population.
  
  
• Diastolic Target: The target for diastolic BP (DBP) is uniformly <80 mmHg for all treated adults, but not below 70 mmHg, to mitigate the risk of adverse coronary events (J-curve phenomenon).
  
  

Specific Comorbidity Targets 

The guidelines maintain specific, nuanced BP targets for patients with key cardiovascular comorbidities, recognizing that certain conditions alter the risk/benefit ratio of intensive BP lowering.

The Special Case of the Elderly 

For patients aged ≥ 80 years, the guidelines adopt a more cautious approach, prioritizing safety and quality of life over aggressive lowering, especially in those who are frail.

• Initial SBP Target: Start treatment if SBP is ≥ 160 mmHg, with a target of 140–130 mmHg.
  
  
• Frailty Consideration: In frail or dependent elderly patients, the intensity of BP lowering should be individualized and may remain higher than in fit patients.
  
  

Pharmacologic Management: The Stepped-Care Strategy 

The 2023 ESC/ESH Guidelines fundamentally reinforce a stepped-care strategy for pharmacologic management, placing heavy emphasis on the immediate use of dual-agent therapy to ensure rapid and effective blood pressure (BP) control. 

The guidelines recognize that monotherapy is insufficient for most patients and a delay in reaching target BP is a major contributor to residual cardiovascular risk.

The Principle of Single-Pill Combination (SPC) Therapy: Class I Recommendation 

The most significant therapeutic shift is the Class I, Level A recommendation that initial treatment should consist of a Single-Pill Combination (SPC) therapy for the majority of patients.

• Rationale: SPCs combine two different drug classes in a single tablet. This approach enhances efficacy through synergistic mechanisms, significantly improves patient adherence (by reducing pill burden), and simplifies the titration process.
  
  
• Exception: Monotherapy may be considered only in patients with low-risk Grade 1 hypertension (SBP <150 mmHg) and no evidence of organ damage or comorbidities, or in very frail elderly patients.
  
  

Step 1: Dual Combination Therapy 

Initial therapy combines two major drug classes, ideally delivered as an SPC. The preferred backbone combination is built upon agents that block the Renin-Angiotensin-Aldosterone System (RAAS), coupled with either a Calcium Channel Blocker (CCB) or a Diuretic.

• Preferred Combination: RAAS Inhibitor (either an Angiotensin-Converting Enzyme inhibitor [ACEi] or an Angiotensin Receptor Blocker [ARB]) + Dihydropyridine CCB (e.g., amlodipine) or Diuretic (e.g., a thiazide/thiazide-like diuretic like indapamide or chlorthalidone).
  
  

Step 2: Triple Combination Therapy 

If BP targets are not achieved on the maximum tolerated doses of Step 1 dual therapy, the treatment is advanced to a triple combination, preferably still within an SPC format to maintain adherence.

• Combination: RAAS Inhibitor (ACEi/ARB) + CCB + Diuretic.
  
  
• Titration: The failure to achieve control at this stage often signals the need to check adherence, assess for secondary causes, and ensure optimal dosing before moving to the final step.
  
  

Step 3: Resistant Hypertension 

Resistant hypertension is defined as BP that remains above target despite adherence to a Step 2 triple combination (RAAS inhibitor, CCB, and diuretic) at optimal or maximum tolerated doses.

• Treatment Strategy: The primary intervention is the addition of a fourth agent, with a Mineralocorticoid Receptor Antagonist (MRA), typically spironolactone, being the preferred choice (Class IIa, Level B), based on trials such as the PATHWAY-2 study.
  
  
• Alternatives: If an MRA is contraindicated or not tolerated, alternative fourth agents include a higher dose of diuretic (e.g., chlorthalidone), an alpha-blocker (e.g., doxazosin), or a beta-blocker.
  
  

Non-Pharmacologic Interventions: Lifestyle Modifications as Foundational Therapy 

While pharmacotherapy is the primary focus of the stepped approach, non-pharmacologic lifestyle interventions are mandatory and form the foundation of management at every stage:

• Dietary: Salt restriction (target <5 g/day), potassium-rich foods, and the Dietary Approaches to Stop Hypertension (DASH) diet.
  
  
• Physical Activity: Regular moderate aerobic exercise (30–45 minutes, 5–7 days per week).
  
  
• Moderation: Limiting alcohol intake and maintaining a healthy body weight (BMI 20-25 kg/m²).
  
  

Clinical Practice Summary and Key Takeaways 

The 2023 ESC/ESH Guidelines on arterial hypertension signal a strong commitment to intensified, yet simplified, management. 

The principal message for healthcare professionals is the necessity of early and aggressive BP lowering using combination therapy to minimize residual cardiovascular risk.

Practice Highlights: Summary of Class I Recommendations

Implications for Real-World Practice 

The guidelines emphasize a logical, stepped therapeutic approach. The immediate use of SPC therapy (Step 1) is intended to overcome therapeutic inertia, which is a major barrier to effective BP control globally. By accelerating the achievement of BP goals, clinicians can realize the full benefits demonstrated in major randomized controlled trials faster.

The revised focus on lower SBP targets (130–120 mmHg) requires careful titration, particularly in older or more frail patients, to manage tolerability and prevent orthostatic hypotension. However, for fit adults with high cardiovascular risk, the data unequivocally support this intensive approach. 

The structured framework—Dual Combination → Triple Combination → Resistant Hypertension strategy—provides a clear, evidence-based pathway for managing the majority of the hypertensive population efficiently.